Bioavailability Contract Manufacturing Marketing Production 
Roots Analysis
FEBRUARY 20, 2022
In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization.
Pharmaceutical Technology
JUNE 14, 2023
The number of high-potency drug approvals has increased over the last decade, driven by the increasing use of APIs (Active Pharmaceutical Ingredients) in the pipeline and among marketed drugs. Containment challenges and opportunities High containment facilities guard against exposure to extremely potent products and cross-contamination.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 12, 2023
Containment and controlled substance capabilities are defining and necessary features for these manufacturing facilities, but not all contract manufacturers have the specialist equipment and capabilities required for high potency small molecule API production. Critical control points are established.
Roots Analysis
MARCH 13, 2022
In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage.
The Pharma Data
JANUARY 27, 2021
As a bioscience accelerator at the leading-edge of the life science industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. . VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp.
Expert insights. Personalized for you.
52 
Let's personalize your content